

Kenneth J Pienta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4377177/kenneth-j-pienta-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

534
papers

50,978
citations

110
h-index

216
g-index

600
ext. papers

58,041
ext. citations

7.8
avg, IF

7.39
L-index

#	Paper	IF	Citations
534	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.. <i>Prostate Cancer and Prostatic Diseases</i> , 2022 ,	6.2	1
533	Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 35-35	2.2	
532	Transcriptomic discriminators of response to apalutamide in patients with prostate cancer (PC) on active surveillance (AS).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 267-267	2.2	
531	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with F-DCFPyL.. <i>Molecular Imaging</i> , 2022 , 2022, 7056983	3.7	0
530	Robots as models of evolving systems.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2120019119	11.5	3
529	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.. <i>Medical Oncology</i> , 2022 , 39, 63	3.7	1
528	Abstract B022: The polyan euploid transition as a hedge against failures in resistance acquisition. <i>Cancer Research</i> , 2022 , 82, B022-B022	10.1	
527	Abstract IA017: The polyan euploid cancer cell state as a mediator of therapeutic resistance. <i>Cancer Research</i> , 2022 , 82, IA017-IA017	10.1	
526	Abstract A001: Modeling cancer ecological and evolutionary dynamics. <i>Cancer Research</i> , 2022 , 82, A001-A001	10.1	
525	Abstract B015: Eco-evolutionary dynamics of poly-aneuploid cancer cells: A life history model. <i>Cancer Research</i> , 2022 , 82, B015-B015	10.1	
524	Measurement of PET Quantitative Bias In Vivo. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 732-737	8.9	0
523	Cell-morphodynamic phenotype classification with application to cancer metastasis using cell magnetorotation and machine-learning. <i>PLoS ONE</i> , 2021 , 16, e0259462	3.7	0
522	Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. <i>Urology</i> , 2021 ,	1.6	1
521	720 CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies 2021 , 9, A749-A749		
520	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 5948-5962	10.1	3
519	It doesn't always pay to be fit: success landscapes. <i>Journal of Biological Physics</i> , 2021 , 47, 387-400	1.6	1
518	Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 1623	10.1	1

517	High KIFC1 expression is associated with poor prognosis in prostate cancer. <i>Medical Oncology</i> , 2021 , 38, 47	3.7	2
516	Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms. <i>Journal of Extracellular Vesicles</i> , 2021 , 10, e12079	16.4	29
515	Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. <i>Diagnostics</i> , 2021 , 11,	3.8	3
514	Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models. <i>Prostate</i> , 2021 , 81, 629-647	4.2	1
513	ROS-induced cell cycle arrest as a mechanism of resistance in polyan euploid cancer cells (PACCs). <i>Progress in Biophysics and Molecular Biology</i> , 2021 , 165, 3-7	4.7	7
512	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021 , 79, 736-746	10.2	0
511	Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer. <i>Medical Oncology</i> , 2021 , 38, 80	3.7	1
510	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. <i>European Urology</i> , 2021 , 79, 762-771	10.2	13
509	Polyaneuploid Cancer Cell Dormancy: Lessons From Evolutionary Phyla. <i>Frontiers in Ecology and Evolution</i> , 2021 , 9,	3.7	1
508	Reply by Authors. <i>Journal of Urology</i> , 2021 , 206, 61	2.5	2
507	The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	1
506	Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro. <i>Medical Oncology</i> , 2021 , 38, 105	3.7	1
505	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021 , 4, 447-455	6.7	20
504	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 387-395	4	11
503	CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer. <i>Prostate</i> , 2021 , 81, 127-134	4.2	3
502	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 220-232	6.2	
501	Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , 2021 , 4, 310-314	6.7	13
500	The role of liquid biopsies in prostate cancer management. <i>Lab on A Chip</i> , 2021 , 21, 3263-3288	7.2	2

499	Detection of Early Progression with F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1270-1273	8.9	1
498	Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyan euploid cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	15
497	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021 , 80, 632-640	10.2	14
496	High-Throughput Simultaneous mRNA Profiling Using nCounter Technology Demonstrates That Extracellular Vesicles Contain Different mRNA Transcripts Than Their Parental Prostate Cancer Cells. <i>Analytical Chemistry</i> , 2021 , 93, 3717-3725	7.8	7
495	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1430-1437	8.9	4
494	Understanding the tumor-immune microenvironment in prostate cancer. <i>Current Opinion in Oncology</i> , 2021 , 33, 231-237	4.2	1
493	Identifying key questions in the ecology and evolution of cancer. <i>Evolutionary Applications</i> , 2021 , 14, 877-892	4.8	17
492	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPNEY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 32-32	2.2	0
491	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021 , 80, 82-94	10.2	21
490	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPNEY). <i>Journal of Urology</i> , 2021 , 206, 52-61	2.5	41
489	Lipid droplet evolution gives insight into polyan euploid cancer cell lipid droplet functions. <i>Medical Oncology</i> , 2021 , 38, 133	3.7	1
488	Cancer cell foraging to explain bone-specific metastatic progression. <i>Bone</i> , 2020 , 115788	4.7	2
487	Game Theory Cancer Models of Cancer Cell-Stromal Cell Dynamics using Interacting Particle Systems. <i>Biophysical Reviews and Letters</i> , 2020 , 15, 171-193	1.2	1
486	The issues with tissues: the wide range of cell fate separation enables the evolution of multicellularity and cancer. <i>Medical Oncology</i> , 2020 , 37, 62	3.7	2
485	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , 2020 , 20, 492	4.8	6
484	An in vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapes. <i>Lab on A Chip</i> , 2020 , 20, 2453-2464	7.2	3
483	Extracellular vesicle isolation from human renal cancer tissue. <i>Medical Oncology</i> , 2020 , 37, 28	3.7	16
482	Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem Engineers. <i>Cancer Control</i> , 2020 , 27, 1073274820911058	2.2	7

481	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. <i>Translational Oncology</i> , 2020 , 13, 100747	4.9	18
480	The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer. <i>BJU International</i> , 2020 , 126, 191-201	5.6	3
479	Poly-aneuploid cancer cells promote evolvability, generating lethal cancer. <i>Evolutionary Applications</i> , 2020 , 13, 1626-1634	4.8	23
478	CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. <i>Clinical Cancer Research</i> , 2020 , 26, 1953-1964	12.9	19
477	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 650-659	13.4	297
476	A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9-9	2.2	7
475	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate CancEr (ORIOLE).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 116-116	2.2	1
474	Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer. <i>Oncotarget</i> , 2020 , 11, 4253-4265	3.3	0
473	Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 525-525	2.2	
472	A phase II randomized trial of Radium-223 dichloride and SABR versus SABR for oligometastatic prostate cancer (RAVENS).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5586-TPS5586	2.2	
471	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2020 , 204, 496-502	2.5	9
470	Letter to the Editor re: "Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake". <i>Molecular Imaging and Biology</i> , 2020 , 22, 19-21	3.8	
469	Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020 , 5, 260-268	3.3	11
468	Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2020 , 80, 113-132	4.2	11
467	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020 , 80, 1273-1296	4.2	11
466	Prospective evaluation of Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level. <i>Medical Oncology</i> , 2020 , 37, 89	3.7	2
465	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Inpatient and Interpatient Variability of Normal Organ Uptake. <i>Molecular Imaging and Biology</i> , 2020 , 22, 181-189	3.8	7
464	Prospective Evaluation of PSMA-Targeted F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 58-61	8.9	39

463	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. <i>Molecular Imaging and Biology</i> , 2020 , 22, 190-197	3.8	16
462	Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer. <i>European Urology</i> , 2020 , 77, 285	10.2	
461	Prospective Comparison of PET Imaging with PSMA-Targeted F-DCFPyL Versus NaF for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 183-188	8.9	13
460	NF-B p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma 2020 , 8,		6
459	Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer. <i>Molecular Cancer Research</i> , 2020 , 18, 801-810	6.6	26
458	Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium. <i>Journal of Extracellular Vesicles</i> , 2020 , 10, e12044	16.4	36
457	Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer. <i>Prostate</i> , 2019 , 79, 1715-1727	4.2	10
456	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 948-956	4	21
455	Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative Radiation for OLigometastatic Prostate CancER (ORIOLE). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 681	4	14
454	Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. <i>Radiotherapy and Oncology</i> , 2019 , 141, 137-143	5.3	2
453	Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2883-2899	16.6	74
452	Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. <i>Molecular Cancer</i> , 2019 , 18, 94	42.1	114
451	Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2019 , 49, 255-270	5.4	42
450	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , 2019 , 37, 923-931 ²		42
449	Novel Structured Reporting Systems for Theranostic Radiotracers. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 577-584	8.9	13
448	Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2019 , 21, 1054-1063	3.8	7
447	PSMA-targeted [F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. <i>Urology Case Reports</i> , 2019 , 23, 72-74	0.5	2
446	Recent advances in extracellular vesicle research for urological cancers: From technology to application. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019 , 1871, 342-360	11.2	9

445	Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2019 , 9, 10	5.3	26
444	The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells. <i>Clinical and Experimental Metastasis</i> , 2019 , 36, 97-108	4.7	32
443	Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance. <i>Prostate</i> , 2019 , 79, 1489-1497	4.2	71
442	CLASSIFICATION OF TUMORS, THEIR FREQUENCY AND PROGRESSION 2019 , 167-211		
441	Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5012-5012	2.2	1
440	Uptake of prostate-specific membrane antigen-targeted F-DCFPyL in avascular necrosis of the femoral head. <i>World Journal of Nuclear Medicine</i> , 2019 , 18, 416-419	0.6	1
439	Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. <i>World Journal of Nuclear Medicine</i> , 2019 , 18, 424-427	0.6	0
438	Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	2
437	Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. <i>European Urology Oncology</i> , 2019 , 2, 429-436	6.7	23
436	Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. <i>Clinical Nuclear Medicine</i> , 2019 , 44, e313-e314	1.7	1
435	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. <i>World Journal of Urology</i> , 2019 , 37, 2623-2629	4	15
434	Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 511-516	8.9	16
433	Optimization of prostate cancer cell detection using multiplex tyramide signal amplification. <i>Journal of Cellular Biochemistry</i> , 2019 , 120, 4804-4812	4.7	8
432	Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. <i>Nature Reviews Urology</i> , 2019 , 16, 7-22	5.5	22
431	Cooperation among cancer cells: applying game theory to cancer. <i>Nature Reviews Cancer</i> , 2019 , 19, 110-117	11.7	52
430	Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2019 , 79, 244-258	4.2	10
429	Metastatic prostate cancer remains incurable, why?. <i>Asian Journal of Urology</i> , 2019 , 6, 26-41	2.7	58
428	AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. <i>Molecular Cancer Research</i> , 2019 , 17, 356-369	6.6	24

427	PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis. <i>Prostate</i> , 2018 , 78, 547-559	4.2	8
426	A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted F-DCFPyL Positron Emission Tomography Imaging. <i>Urology</i> , 2018 , 117, 18-21	1.6	11
425	Targeting the tumour stroma to improve cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 366-381	19.4	421
424	CXCL12 Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. <i>Cancer Research</i> , 2018 , 78, 2026-2039	10.1	29
423	Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method. <i>Urology</i> , 2018 , 115, 82-86	1.6	14
422	Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 8074-8083	4.7	11
421	Cancer dormancy and criticality from a game theory perspective 2018 , 2, 1		3
420	Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. <i>Urology Case Reports</i> , 2018 , 17, 22-25	0.5	5
419	Analogous detection of circulating tumor cells using the AccuCyte -CyteFinder system and ISET system in patients with locally advanced and metastatic prostate cancer. <i>Prostate</i> , 2018 , 78, 300-307	4.2	15
418	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. <i>Prostate</i> , 2018 , 78, 775-789	4.2	25
417	Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. <i>Journal of Urology</i> , 2018 , 199, 1494-1501	2.5	17
416	SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1085-1091	8.9	28
415	Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 486-493	8.9	17
414	Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 479-485	8.9	81
413	Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 539-548	6.2	61
412	Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1431-1432	13.4	3
411	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. <i>Annals of Nuclear Medicine</i> , 2018 , 32, 512-522	2.5	22
410	Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells. <i>Biological Procedures Online</i> , 2018 , 20, 13	8.3	12

409	Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells. <i>PLoS ONE</i> , 2018 , 13, e0191188	3.7	7
408	Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. <i>Journal of Clinical Investigation</i> , 2018 , 128, 248-266	15.9	62
407	O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4924-4937	15.9	24
406	A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS5092-TPS5092 ²	2.2	2
405	Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 79-79	2.2	2
404	Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem. <i>Oncotarget</i> , 2018 , 9, 11429-11440	3.3	15
403	Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018 , 73, 478	10.2	
402	Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT. <i>Urology Case Reports</i> , 2018 , 16, 86-88	0.5	4
401	Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests. <i>JAMA Oncology</i> , 2018 , 4, 868-870	13.4	114
400	Prostate Specific Membrane Antigen Targeted F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. <i>Journal of Urology</i> , 2018 , 199, 126-132	2.5	69
399	Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. <i>Oncotarget</i> , 2018 , 9, 20908-20927	3.3	57
398	Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas. <i>Clinical Nuclear Medicine</i> , 2018 , 43, e419-e421 ⁷	1.7	17
397	3D Cell Nuclear Morphology: Microscopy Imaging Dataset and Voxel-Based Morphometry Classification Results 2018 ,		8
396	Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, e134-e135	4	2
395	Cancer Foraging Ecology: Diet Choice, Patch Use, and Habitat Selection of Cancer Cells. <i>Current Pathobiology Reports</i> , 2018 , 6, 209-218	2	10
394	Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on F-DCFPyL PET/CT Imaging. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1857-1864	8.9	28
393	3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification. <i>Scientific Reports</i> , 2018 , 8, 13658	4.9	11
392	Cancer as a Social Dysfunction-Why Cancer Research Needs New Thinking. <i>Molecular Cancer Research</i> , 2018 , 16, 1346-1347	6.6	6

391	A surface tension magnetophoretic device for rare cell isolation and characterization. <i>Medical Oncology</i> , 2017 , 34, 22	3.7	4
390	Biomanufacturing Seamless Tubular and Hollow Collagen Scaffolds with Unique Design Features and Biomechanical Properties. <i>Advanced Healthcare Materials</i> , 2017 , 6, 1601136	10.1	12
389	Revisiting Seed and Soil: Examining the Primary Tumor and Cancer Cell Foraging in Metastasis. <i>Molecular Cancer Research</i> , 2017 , 15, 361-370	6.6	57
388	Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e477-e481	3.3	12
387	TWIST1-WDR5- Regulates Chromatin to Facilitate Prostate Cancer Metastasis. <i>Cancer Research</i> , 2017 , 77, 3181-3193	10.1	68
386	The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. <i>Molecular Oncology</i> , 2017 , 11, 655-669	7.9	26
385	The Identification of Macrophage-enriched Glycoproteins Using Glycoproteomics. <i>Molecular and Cellular Proteomics</i> , 2017 , 16, 1029-1037	7.6	12
384	RB Loss Promotes Prostate Cancer Metastasis. <i>Cancer Research</i> , 2017 , 77, 982-995	10.1	47
383	Semiquantitative Parameters in PSMA-Targeted PET Imaging with F-DCFPyL: Variability in Normal-Organ Uptake. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 942-946	8.9	35
382	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. <i>Cancer Cell</i> , 2017 , 32, 474-489.e6	24.3	280
381	Cancer Genetics, Cancer Biology, and Tumor Growth and Metastasis 2017 , 1-18		
380	Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted F-DCFPyL in peripheral ganglia. <i>Annals of Nuclear Medicine</i> , 2017 , 31, 696-702	2.5	25
379	Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype. <i>Oncotarget</i> , 2017 , 8, 98598-98608	3.3	10
378	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2149-2156	2.2	279
377	An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. <i>Clinical Nuclear Medicine</i> , 2017 , 42, e441-e443	1.7	1
376	Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. <i>Convergent Science Physical Oncology</i> , 2017 , 3,		10
375	Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i> , 2017 , 17, 605-619	5.1	208
374	Tenascin-C and Integrin α 9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. <i>Cancer Research</i> , 2017 , 77, 5977-5988	10.1	37

373	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017 , 77, 1478-1488	4.2	2
372	Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. <i>Current Opinion in Urology</i> , 2017 , 27, 533-541	2.8	23
371	Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. <i>Nuclear Medicine Communications</i> , 2017 , 38, 795-798	1.6	4
370	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2117-2136	8.8	162
369	Prostate Cancer Local Recurrence Detected With Both F-Fluciclovine and PSMA-targeted F-DCFPyL PET/CT. <i>Urology</i> , 2017 , 107, e9-e10	1.6	6
368	Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration. <i>BMC Cancer</i> , 2017 , 17, 447	4.8	11
367	A phase II randomized trial of Observation versus stereotactic ablative Radiation for OLigometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , 2017 , 17, 453	4.8	60
366	Correlation of PSMA-Targeted F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e65-e68	3.3	42
365	Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. <i>European Urology</i> , 2017 , 72, 135-141	10.2	15
364	A Bayesian hierarchical model for prediction of latent health states from multiple data sources with application to active surveillance of prostate cancer. <i>Biometrics</i> , 2017 , 73, 625-634	1.8	19
363	Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance. <i>BJU International</i> , 2017 , 120, 25-31	5.6	23
362	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017 , 77, 123-144	4.2	4
361	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. <i>Nature Reviews Urology</i> , 2017 , 14, 15-25	5.5	138
360	Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. <i>Nature Reviews Urology</i> , 2017 , 14, 90-97	5.5	60
359	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5020-5020	2.2	2
358	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5094-TPS5094	2.2	
357	A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5078-5078	2.2	
356	Positive Feedback Loops Between Inflammatory, Bone and Cancer Cells During Metastatic Niche Construction. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 936, 137-148	3.6	3

355	Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	83
354	Murine Prostate Micro-dissection and Surgical Castration. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	8
353	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. <i>Advances in Radiation Oncology</i> , 2016 , 1, 59-66	3.3	4
352	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2016 , 76, 125-39	4.2	12
351	PSMA-Based Detection of Prostate Cancer Bone Lesions With ^{68}Ga -DCFPyL PET/CT: A Sensitive Alternative to $^{99\text{m}}\text{Tc}$ -MDP Bone Scan and ^{18}F PET/CT?. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e115-8	3.3	46
350	Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E854-63	11.5	399
349	Disseminated tumor cells and dormancy in prostate cancer metastasis. <i>Current Opinion in Biotechnology</i> , 2016 , 40, 9-15	11.4	47
348	Ecological paradigms to understand the dynamics of metastasis. <i>Cancer Letters</i> , 2016 , 380, 237-42	9.9	32
347	AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5012-5012	2.2	8
346	Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. <i>PLoS ONE</i> , 2016 , 11, e0147400	3.7	62
345	Technical challenges in the isolation and analysis of circulating tumor cells. <i>Oncotarget</i> , 2016 , 7, 62754-62766	3.7	66
344	A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow. <i>Oncotarget</i> , 2016 , 7, 69794-69803	3.3	5
343	The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. <i>Oncotarget</i> , 2016 , 7, 41217-41232	3.3	48
342	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 103-103	2.2	
341	Development of an automated and sensitive microfluidic device for circulating tumor cell (CTC) analysis and single cell capturing.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23031-e23031	2.2	
340	Computer extracted nuclear features from Feulgen and H&E images to predict biochemical recurrence in prostate cancer patients following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5067-5067	2.2	
339	Computer extracted features on H&E images to improve biochemical recurrence prediction of Kattan nomogram for prostate cancer patients following radical prostatectomy: Preliminary findings.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11556-11556	2.2	
338	Stability of the hybrid epithelial/mesenchymal phenotype. <i>Oncotarget</i> , 2016 , 7, 27067-84	3.3	259

337	A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cells. <i>BioTechniques</i> , 2016 , 61, 33-41	2.5	47
336	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. <i>Urology Case Reports</i> , 2016 , 6, 45-6	0.5	
335	Role of biobanking in urology: a review. <i>BJU International</i> , 2016 , 118, 864-868	5.6	5
334	Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E6457-E6466	11.5	32
333	DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis. <i>Neoplasia</i> , 2016 , 18, 553-66	6.4	74
332	A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 294-302	4	45
331	Drug discovery in prostate cancer mouse models. <i>Expert Opinion on Drug Discovery</i> , 2015 , 10, 1011-24	6.2	12
330	Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts. <i>Medical Oncology</i> , 2015 , 32, 159	3.7	17
329	A multi-targeted approach to treating bone metastases 2015 , 647-655		
328	Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure. <i>Prostate</i> , 2015 , 75, 218-24	4.2	11
327	Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes. <i>Urology</i> , 2015 , 85, 147-53	1.6	45
326	The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor. <i>Journal of Cellular Biochemistry</i> , 2015 , 116, 115-23	4.7	12
325	Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer. <i>PLoS ONE</i> , 2015 , 10, e0123877	3.7	9
324	Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. <i>Oncotarget</i> , 2015 , 6, 9669-78	3.3	54
323	The biology and treatment of oligometastatic cancer. <i>Oncotarget</i> , 2015 , 6, 8491-524	3.3	171
322	Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. <i>Oncotarget</i> , 2015 , 6, 130-43	3.3	99
321	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
320	Oligometastatic prostate cancer to the navicular bone: case report. <i>Urology Case Reports</i> , 2015 , 3, 59-62	0.5	2

319	Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. <i>Prostate</i> , 2015 , 75, 337-47	4.2	9
318	Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide. <i>PLoS ONE</i> , 2015 , 10, e0143161	3.7	21
317	OVOL guides the epithelial-hybrid-mesenchymal transition. <i>Oncotarget</i> , 2015 , 6, 15436-48	3.3	92
316	Coupling the modules of EMT and stemness: A tunable 'stemness window' model. <i>Oncotarget</i> , 2015 , 6, 25161-74	3.3	116
315	Bone marrow macrophages support prostate cancer growth in bone. <i>Oncotarget</i> , 2015 , 6, 35782-96	3.3	39
314	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2015 , 17, 936-8; discussion 938	2.8	1
313	Targeting Efferocytic M2 Monocytes and Macrophages Offers Therapeutic Promise in Prostate Cancer Skeletal Metastasis. <i>FASEB Journal</i> , 2015 , 29, LB457	0.9	
312	Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. <i>Cancer Cell</i> , 2014 , 25, 638-651	24.3	216
311	Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering. <i>Journal of Cellular Biochemistry</i> , 2014 , 115, 1478-85	4.7	39
310	Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. <i>Molecular Pharmacology</i> , 2014 , 85, 866-76	4.3	24
309	Critical transitions in a game theoretic model of tumour metabolism. <i>Interface Focus</i> , 2014 , 4, 20140014	3.9	35
308	A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial - mesenchymal cell reprogramming and cancer progression. <i>BMC Systems Biology</i> , 2014 , 8, 29	3.5	11
307	Response to "Comment on 'A method to measure cellular adhesion utilizing a polymer micro-cantilever'" [Appl. Phys. Lett. , 236103 (2014)]. <i>Applied Physics Letters</i> , 2014 , 104, 236104	3.4	1
306	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
305	Axl as a mediator of cellular growth and survival. <i>Oncotarget</i> , 2014 , 5, 8818-52	3.3	112
304	Endothelial integrin $\beta 1$ stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane. <i>Oncotarget</i> , 2014 , 5, 1382-9	3.3	21
303	Genetic ablation of metadherin inhibits autochthonous prostate cancer progression and metastasis. <i>Cancer Research</i> , 2014 , 74, 5336-47	10.1	29
302	TAM macrophages promote growth and metastasis within the cancer ecosystem. <i>OncImmunology</i> , 2014 , 3, e941734	7.2	27

301	Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. <i>Prostate</i> , 2014 , 74, 1199-208	4.2	25
300	Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. <i>Journal of Biological Chemistry</i> , 2014 , 289, 24560-72	5.4	106
299	Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting. <i>Prostate</i> , 2014 , 74, 314-20	4.2	12
298	Molecular Mechanisms of Prostate Cancer Progression After Castration. <i>Current Clinical Urology</i> , 2014 , 31-41		
297	A multi-targeted approach to treating bone metastases. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 545-53	6	12
296	Circulating fibroblast-like cells in men with metastatic prostate cancer. <i>Prostate</i> , 2013 , 73, 176-81	4.2	34
295	TBK1 regulates prostate cancer dormancy through mTOR inhibition. <i>Neoplasia</i> , 2013 , 15, 1064-74	6.4	79
294	The long noncoding RNA SchLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. <i>Nature Genetics</i> , 2013 , 45, 1392-8	36.3	515
293	Identification of targetable FGFR gene fusions in diverse cancers. <i>Cancer Discovery</i> , 2013 , 3, 636-47	24.4	511
292	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. <i>Nature Genetics</i> , 2013 , 45, 180-5	36.3	514
291	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. <i>Nature Genetics</i> , 2013 , 45, 1446-51	36.3	742
290	Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. <i>Journal of Cellular Biochemistry</i> , 2013 , 114, 2471-8	4.7	9
289	New and emerging therapies for bone metastases in genitourinary cancers. <i>European Urology</i> , 2013 , 63, 309-20	10.2	36
288	Words of wisdom: re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. <i>European Urology</i> , 2013 , 64, 339-40	10.2	6
287	Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. <i>Nature Communications</i> , 2013 , 4, 1795	17.4	269
286	Cancer stem cells and their role in metastasis. <i>Pharmacology & Therapeutics</i> , 2013 , 138, 285-93	13.9	152
285	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013 , 31, 760-8	4.3	220
284	The cancer diaspora: Metastasis beyond the seed and soil hypothesis. <i>Clinical Cancer Research</i> , 2013 , 19, 5849-55	12.9	76

283	Definition of molecular determinants of prostate cancer cell bone extravasation. <i>Cancer Research</i> , 2013 , 73, 942-52	10.1	52
282	Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 20111-6	11.5	114
281	Metastatic castration-resistant prostate cancer reveals inpatient similarity and interpatient heterogeneity of therapeutic kinase targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E4762-9	11.5	82
280	A method to measure cellular adhesion utilizing a polymer micro-cantilever. <i>Applied Physics Letters</i> , 2013 , 103, 123702	3.4	8
279	GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. <i>PLoS ONE</i> , 2013 , 8, e61873	3.7	96
278	Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. <i>PLoS ONE</i> , 2013 , 8, e76773	3.7	163
277	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. <i>PLoS ONE</i> , 2013 , 8, e69239	3.7	124
276	Forging the Association for Clinical and Translational Science (ACTS). <i>Clinical and Translational Science</i> , 2012 , 5, 117-8	4.9	0
275	Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2012 , 30, 749-57	4.3	66
274	Disrupting the networks of cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 2801-8	12.9	30
273	Role of transcriptional corepressor CtBP1 in prostate cancer progression. <i>Neoplasia</i> , 2012 , 14, 905-14	6.4	49
272	Systemic delivery of oncolytic adenoviruses targeting transforming growth factor- β inhibits established bone metastasis in a prostate cancer mouse model. <i>Human Gene Therapy</i> , 2012 , 23, 871-82	4.8	54
271	Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. <i>Molecular Cancer Research</i> , 2012 , 10, 703-12	6.6	76
270	The mutational landscape of lethal castration-resistant prostate cancer. <i>Nature</i> , 2012 , 487, 239-43	50.4	1708
269	Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. <i>Neoplasia</i> , 2012 , 14, 429-39	6.4	47
268	Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. <i>Neoplasia</i> , 2012 , 14, 65-73	6.4	65
267	Prostate cancer and parasitism of the bone hematopoietic stem cell niche. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2012 , 22, 131-48	1.3	21
266	Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. <i>Prostate</i> , 2012 , 72, 1542-9	4.2	12

265	384 hanging drop arrays give excellent Z-factors and allow versatile formation of co-culture spheroids. <i>Biotechnology and Bioengineering</i> , 2012 , 109, 1293-304	4.9	102
264	Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates. <i>Biomedical Microdevices</i> , 2012 , 14, 313-23	3.7	82
263	IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 1569-80	4.7	50
262	Chemical transfection of dye-conjugated microRNA precursors for microRNA functional analysis of M2 macrophages. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 1714-23	4.7	4
261	Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. <i>Cancer Research</i> , 2012 , 72, 616-25	10.1	97
260	Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. <i>Cancer Research</i> , 2012 , 72, 2522-32	10.1	51
259	Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. <i>Molecular Cancer Research</i> , 2012 , 10, 282-92	6.6	37
258	The prostate cancer bone marrow niche: more than just 'fertile soil'. <i>Asian Journal of Andrology</i> , 2012 , 14, 423-7	2.8	44
257	Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. <i>Neoplasia</i> , 2011 , 13, 1019-25	6.4	65
256	Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. <i>Neoplasia</i> , 2011 , 13, 23-30	6.4	44
255	Therapeutic targeting of SPINK1-positive prostate cancer. <i>Science Translational Medicine</i> , 2011 , 3, 72ra17.5	17.5	120
254	Mechanisms of cancer cell metastasis to the bone: a multistep process. <i>Future Oncology</i> , 2011 , 7, 1285-93.	9.6	118
253	Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. <i>Bone</i> , 2011 , 48, 1354-61	4.7	15
252	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discovery</i> , 2011 , 1, 487-95	24.4	550
251	The Clinical and Translational Science Awards (CTSAs) are transforming the way academic medical institutions approach translational research: the University of Michigan Experience. <i>Clinical and Translational Science</i> , 2011 , 4, 233-5	4.9	3
250	Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. <i>Cancer Cell</i> , 2011 , 19, 664-78	24.3	342
249	Personalized oncology through integrative high-throughput sequencing: a pilot study. <i>Science Translational Medicine</i> , 2011 , 3, 111ra121	17.5	452
248	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2011 , 29, 1432-40	4.3	44

247	Homing of cancer cells to the bone. <i>Cancer Microenvironment</i> , 2011 , 4, 221-35	6.1	54
246	Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles. <i>Theoretical Biology and Medical Modelling</i> , 2011 , 8, 36	2.3	23
245	Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 125-34	6.3	31
244	Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. <i>Genome Research</i> , 2011 , 21, 47-55	9.7	134
243	Characterization of bone metastases from rapid autopsies of prostate cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 3924-32	12.9	60
242	Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. <i>Clinical Cancer Research</i> , 2011 , 17, 1546-52	12.9	15
241	Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 5553-8	12.9	69
240	Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1298-312	15.9	547
239	Nanoparticle induced cell magneto-rotation: monitoring morphology, stress and drug sensitivity of a suspended single cancer cell. <i>PLoS ONE</i> , 2011 , 6, e28475	3.7	29
238	Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. <i>Cancer Research</i> , 2010 , 70, 471-80	10.1	76
237	Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 522-8	9.7	177
236	Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. <i>Progress in Molecular Biology and Translational Science</i> , 2010 , 95, 31-53	4	66
235	CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. <i>Cytokine and Growth Factor Reviews</i> , 2010 , 21, 41-8	17.9	204
234	GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. <i>Neoplasia</i> , 2010 , 12, 116-27	6.4	220
233	The CTSA mandate: are we there yet?. <i>Research and Theory for Nursing Practice</i> , 2010 , 24, 64-73	0.8	4
232	Single cell trapping in larger microwells capable of supporting cell spreading and proliferation. <i>Microfluidics and Nanofluidics</i> , 2010 , 8, 263-268	2.8	70
231	CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. <i>Cancer and Metastasis Reviews</i> , 2010 , 29, 709-22	9.6	543
230	Successfully accelerating translational research at an academic medical center: the University of Michigan-Coulter translational research partnership program. <i>Clinical and Translational Science</i> , 2010 , 3, 316-8	4.9	15

229	AT-101 (R(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. <i>Journal of Cellular Biochemistry</i> , 2010 , 110, 1187-94	4.7	19
228	Erythropoietin couples hematopoiesis with bone formation. <i>PLoS ONE</i> , 2010 , 5, e10853	3.7	118
227	A Multi-targeted Approach to Treating Bone Metastases 2010 , 441-448		
226	Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 19491-6	11.5	99
225	Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration-Resistant Prostate Cancer: Missing Parts in a Superb Study: Table 1.. <i>Clinical Cancer Research</i> , 2009 , 15, 1504.2-1505	12.9	5
224	A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. <i>Cancer Research</i> , 2009 , 69, 1685-92	10.1	129
223	CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. <i>Journal of Biological Chemistry</i> , 2009 , 284, 34342-54	5.4	372
222	Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. <i>Journal of Cellular Biochemistry</i> , 2009 , 106, 563-9	4.7	24
221	Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. <i>Journal of Cellular Biochemistry</i> , 2009 , 107, 58-64	4.7	57
220	Tomlins et al. reply. <i>Nature</i> , 2009 , 457, E2-E3	50.4	5
219	FYN is overexpressed in human prostate cancer. <i>BJU International</i> , 2009 , 103, 171-7	5.6	68
218	Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary results of the EORTC 22999 International Group of Radiotherapy Oncology Physicians 2009	4	48
217	Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. <i>Biomaterials</i> , 2009 , 30, 3020-7	15.6	238
216	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. <i>Cancer Research</i> , 2009 , 69, 4434-42	10.1	162
215	Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later. <i>Urology</i> , 2009 , 73, S11-20	1.6	37
214	Regulation of prostate cancer progression by galectin-3. <i>American Journal of Pathology</i> , 2009 , 174, 1515-23	5.3	92
213	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. <i>Lancet Oncology</i> , 2009 , 10, 233-9	21.7	476
212	The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. <i>Neoplasia</i> , 2009 , 11, 1235-42	6.4	160

211	CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. <i>Neoplasia</i> , 2009 , 11, 1309-17	6.4	39
210	Possible mechanism of CCL2-induced Akt activation in prostate cancer cells. <i>Anticancer Research</i> , 2009 , 29, 3109-13	2.3	13
209	The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. <i>Leukemia</i> , 2008 , 22, 941-50	10.7	171
208	Re: RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastasis model. <i>European Urology</i> , 2008 , 54, 688	10.2	0
207	-(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. <i>Pharmacological Research</i> , 2008 , 58, 323-31	10.2	33
206	A sequence-based survey of the complex structural organization of tumor genomes. <i>Genome Biology</i> , 2008 , 9, R59	18.3	30
205	Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2192-202	6.1	156
204	Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. <i>Translational Oncology</i> , 2008 , 1, 158-64	4.9	120
203	An in vivo mouse model for human prostate cancer metastasis. <i>Neoplasia</i> , 2008 , 10, 371-80	6.4	64
202	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. <i>Cancer Research</i> , 2008 , 68, 3584-90	10.1	220
201	Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. <i>Clinical Cancer Research</i> , 2008 , 14, 7701-10	12.9	49
200	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3933-8	11.5	574
199	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 6302-9	12.9	1685
198	CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. <i>Journal of Biological Chemistry</i> , 2008 , 283, 25057-73	5.4	130
197	The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. <i>Journal of Biological Chemistry</i> , 2008 , 283, 4283-94	5.4	381
196	CCL2, survivin and autophagy: new links with implications in human cancer. <i>Autophagy</i> , 2008 , 4, 969-71	10.2	42
195	CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. <i>Clinical and Experimental Metastasis</i> , 2008 , 25, 765-76	4.7	67
194	The current state of preclinical prostate cancer animal models. <i>Prostate</i> , 2008 , 68, 629-39	4.2	103

193	Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. <i>Prostate</i> , 2008 , 68, 1396-404	4.2	110
192	Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. <i>International Journal of Cancer</i> , 2008 , 123, 2267-78	7.5	82
191	CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. <i>Journal of Cellular Biochemistry</i> , 2008 , 104, 1587-97	4.7	38
190	Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha. <i>Journal of Cellular Biochemistry</i> , 2008 , 104, 2298-309	4.7	27
189	Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2008 , 105, 370-80	4.7	187
188	Solid Tumors Target the HSC Niche to Establish Metastatic Footholds in the Marrow. <i>Blood</i> , 2008 , 112, 552-552	2.2	
187	A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. <i>Neoplasia</i> , 2007 , 9, 1003-11	6.4	92
186	CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. <i>Neoplasia</i> , 2007 , 9, 556-62	6.4	171
185	Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. <i>Neoplasia</i> , 2007 , 9, 662-70	6.4	77
184	The lethal phenotype of cancer: the molecular basis of death due to malignancy. <i>Ca-A Cancer Journal for Clinicians</i> , 2007 , 57, 225-41	220.7	120
183	Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 318-22	3.3	7
182	PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. <i>Journal of Cellular Biochemistry</i> , 2007 , 101, 1292-300	4.7	29
181	Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. <i>Cancer</i> , 2007 , 110, 2809-18	6.4	239
180	Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. <i>Prostate</i> , 2007 , 67, 61-73	4.2	150
179	Integrative molecular concept modeling of prostate cancer progression. <i>Nature Genetics</i> , 2007 , 39, 41-51	36.3	734
178	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. <i>Modern Pathology</i> , 2007 , 20, 538-44	9.8	250
177	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , 2007 , 448, 595-9	50.4	654
176	Bone metastasis and cancer. <i>Cancer and Metastasis Reviews</i> , 2007 , 25, 505-505	9.6	

175	Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4171-7	2.2	160
174	A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. <i>Cancer Research</i> , 2007 , 67, 10657-63	10.1	270
173	A glycolytic mechanism regulating an angiogenic switch in prostate cancer. <i>Cancer Research</i> , 2007 , 67, 149-59	10.1	127
172	Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. <i>Cancer Research</i> , 2007 , 67, 9417-24	10.1	272
171	An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. <i>Cancer Research</i> , 2007 , 67, 3524-8	10.1	60
170	Integrative analysis of genomic aberrations associated with prostate cancer progression. <i>Cancer Research</i> , 2007 , 67, 8229-39	10.1	96
169	A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. <i>Molecular Cell</i> , 2007 , 27, 380-92	17.6	526
168	In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. <i>Neoplasia</i> , 2007 , 9, 1030-7	6.4	45
167	The evolving biology and treatment of prostate cancer. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2351-61.9	6.9	101
166	Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. <i>Clinical Genitourinary Cancer</i> , 2006 , 4, 299-302	3.3	63
165	Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2006 , 106, 1715-21	6.4	10
164	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. <i>Cancer</i> , 2006 , 106, 2617-23	6.4	4
163	Mechanisms underlying the development of androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 1665-71	12.9	338
162	Modeling somatic evolution in tumorigenesis. <i>PLoS Computational Biology</i> , 2006 , 2, e108	5	74
161	TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. <i>Cancer Research</i> , 2006 , 66, 8337-41	10.1	419
160	Simulating the hallmarks of cancer. <i>Artificial Life</i> , 2006 , 12, 617-34	1.4	70
159	Evolution of cooperation among tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 13474-9	11.5	305
158	CCL2 is a potent regulator of prostate cancer cell migration and proliferation. <i>Neoplasia</i> , 2006 , 8, 578-866.4	6.4	180

157	Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. <i>Neoplasia</i> , 2006 , 8, 69-78	6.4	48
156	Development of the VCaP androgen-independent model of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 161-8	2.8	36
155	GREB1 is a novel androgen-regulated gene required for prostate cancer growth. <i>Prostate</i> , 2006 , 66, 886-94	4.4	55
154	Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. <i>Oncology</i> , 2006 , 71, 168-75	3.6	55
153	Modeling Cancer as A Complex Adaptive System: Genetic Instability and Evolution 2006 , 537-556		
152	Prostate cancer presenting as visual changes. <i>Anticancer Research</i> , 2006 , 26, 755-8	2.3	2
151	Androgens and prostate cancer: are the descriptors valid?. <i>Cancer Biology and Therapy</i> , 2005 , 4, 4-5	4.6	39
150	Autoantibody signatures in prostate cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1224-35	59.2	521
149	Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. <i>Urology</i> , 2005 , 65, 616-21	1.6	32
148	Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. <i>Urology</i> , 2005 , 66, 658	1.6	32
147	Analysis of membrane-bound complement regulatory proteins in prostate cancer. <i>Urology</i> , 2005 , 66, 1321-6	1.6	32
146	Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metalloproteinase expression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005 , 23, 73-74	2.8	
145	The "emigration, migration, and immigration" of prostate cancer. <i>Clinical Prostate Cancer</i> , 2005 , 4, 24-30		45
144	Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2005 , 4, 212-4	3.3	16
143	Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. <i>Neoplasia</i> , 2005 , 7, 522-7	6.4	136
142	Global gene expression profiling of circulating tumor cells. <i>Cancer Research</i> , 2005 , 65, 4993-7	10.1	308
141	Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 318-29	6.3	306
140	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. <i>Science</i> , 2005 , 310, 644-8	33.3	3022

139	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , 2005 , 8, 393-406	24.3	625
138	Advances in prostate cancer chemotherapy: a new era begins. <i>Ca-A Cancer Journal for Clinicians</i> , 2005 , 55, 300-18; quiz 323-5	220.7	128
137	A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. <i>Journal of Cellular Biochemistry</i> , 2005 , 96, 439-46	4.7	32
136	PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. <i>Journal of Cellular Biochemistry</i> , 2005 , 96, 641-52	4.7	72
135	Amplification and overexpression of prosaposin in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2005 , 44, 351-64	5	42
134	Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8232-41	2.2	121
133	Bone turnover mediates preferential localization of prostate cancer in the skeleton. <i>Endocrinology</i> , 2005 , 146, 1727-36	4.8	156
132	Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. <i>Cancer Research</i> , 2005 , 65, 5750-60	10.1	96
131	Drug insight: Use of docetaxel in prostate and urothelial cancers. <i>Nature Reviews Urology</i> , 2005 , 2, 92-100; quiz 1 p following 112		44
130	Proptosis and decreased vision secondary to prostate cancer orbital wall metastasis. <i>Anticancer Research</i> , 2005 , 25, 3521-2	2.3	8
129	Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 537-56	2.2	167
128	Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. <i>Cancer Research</i> , 2004 , 64, 3814-22	10.1	136
127	Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. <i>Cancer Research</i> , 2004 , 64, 9209-16	10.1	712
126	Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells. <i>Journal of Physiology</i> , 2004 , 554, 89-99	3.9	37
125	In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. <i>Prostate</i> , 2004 , 59, 360-9	4.2	38
124	Apoptosis of circulating tumor cells in prostate cancer patients. <i>Cytometry</i> , 2004 , 62, 46-53		111
123	Expression mapping at 12p12-13 in advanced prostate carcinoma. <i>International Journal of Cancer</i> , 2004 , 109, 668-72	7.5	20
122	Cellular interactions in the tropism of prostate cancer to bone. <i>International Journal of Cancer</i> , 2004 , 110, 497-503	7.5	57

121	Dynamic process of prostate cancer metastasis to bone. <i>Journal of Cellular Biochemistry</i> , 2004 , 91, 706-17	7.7	76
120	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. <i>Human Molecular Genetics</i> , 2004 , 13, 1303-13	5.6	158
119	Detection and isolation of circulating tumor cells in urologic cancers: a review. <i>Neoplasia</i> , 2004 , 6, 302-9	6.4	49
118	Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. <i>Neoplasia</i> , 2004 , 6, 503-12	6.4	39
117	Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. <i>Cancer Letters</i> , 2004 , 215, 209-20	9.9	49
116	Testicular cancer. <i>Current Opinion in Oncology</i> , 2004 , 16, 253-6	4.2	8
115	Cancer cells homing to bone: the significance of chemotaxis and cell adhesion. <i>Cancer Treatment and Research</i> , 2004 , 118, 291-309	3.5	14
114	Germ cell tumors: review of selected studies from 2002. <i>Current Opinion in Oncology</i> , 2003 , 15, 234-8	4.2	7
113	Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium. <i>Clinical and Experimental Metastasis</i> , 2003 , 20, 451-8	4.7	25
112	Stromal factors involved in prostate carcinoma metastasis to bone. <i>Cancer</i> , 2003 , 97, 739-47	6.4	158
111	Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2003 , 98, 269-76	6.4	27
110	Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. <i>Cancer</i> , 2003 , 98, 1603-10	6.4	30
109	Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. <i>Journal of Cellular Biochemistry</i> , 2003 , 89, 462-73	4.7	370
108	Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy. <i>Urology</i> , 2003 , 62 Suppl 1, 95-101	1.6	4
107	Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. <i>Urology</i> , 2003 , 62 Suppl 1, 128-33	1.6	28
106	The truth is out there: an overall perspective on androgen deprivation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 272-81	2.8	12
105	Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. <i>Reviews in Urology</i> , 2003 , 5 Suppl 2, S28-34	1	
104	Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. <i>Reviews in Urology</i> , 2003 , 5 Suppl 3, S45-51	1	

103	Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy 2003 , 423-433		1
102	Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. <i>Cancer Research</i> , 2003 , 63, 3805-11	10.1	189
101	In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. <i>Cancer Biology and Therapy</i> , 2003 , 2, 656-60	4.6	26
100	The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 6447-52	12.9	64
99	Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone 2002 , 197-213		
98	The current state of hormonal therapy for prostate cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2002 , 52, 154-79	220.7	279
97	APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. <i>Genes Chromosomes and Cancer</i> , 2002 , 34, 9-16	5	133
96	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , 2002 , 419, 624-9	30.4	2085
95	The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. <i>Clinical and Experimental Metastasis</i> , 2002 , 19, 25-33	4.7	26
94	alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 1662-70	27.4	489
93	Tissue microarray sampling strategy for prostate cancer biomarker analysis. <i>American Journal of Surgical Pathology</i> , 2002 , 26, 312-9	6.7	258
92	Testicular cancer. <i>Current Opinion in Oncology</i> , 2002 , 14, 260-4	4.2	5
91	Antimetastatic drugs in prostate cancer. <i>Clinical Prostate Cancer</i> , 2002 , 1, 14-9		7
90	MIM, a potential metastasis suppressor gene in bladder cancer. <i>Neoplasia</i> , 2002 , 4, 291-4	6.4	131
89	Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. <i>Neoplasia</i> , 2002 , 4, 373-9	6.4	51
88	Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer risk-an unmeasured and masked mediator of potential significance?. <i>Urology</i> , 2002 , 59, 4-8	1.6	6
87	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. <i>Urology</i> , 2002 , 60, 760-5	1.6	83
86	The Role of β in Prostate Cancer Progression. <i>Neoplasia</i> , 2002 , 4, 191-194	6.4	174

85	The role of alpha(v)beta(3) in prostate cancer progression. <i>Neoplasia</i> , 2002 , 4, 191-4	6.4	92
84	Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. <i>Cancer Research</i> , 2002 , 62, 1832-7	10.1	689
83	Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide. <i>Cancer</i> , 2001 , 91, 2175-80	6.4	6
82	A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). <i>Prostate</i> , 2001 , 46, 257-61	4.2	29
81	Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. <i>Cancer and Metastasis Reviews</i> , 2001 , 20, 333-49	9.6	150
80	Delineation of prognostic biomarkers in prostate cancer. <i>Nature</i> , 2001 , 412, 822-6	50.4	1402
79	E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. <i>Human Pathology</i> , 2001 , 32, 690-7	3.7	150
78	Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. <i>Urology</i> , 2001 , 57, 366-70	1.6	24
77	Decreased galectin-3 expression in prostate cancer. <i>Prostate</i> , 2000 , 44, 118-23	4.2	85
76	Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures. <i>Prostate</i> , 2000 , 44, 164-71	4.2	29
75	Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. <i>Prostate</i> , 2000 , 44, 275-8	4.2	30
74	Evidence for lectin signaling to the nuclear matrix: cellular interpretation of the glycode. <i>Journal of Cellular Biochemistry</i> , 2000 , Suppl 35, 123-9	4.7	8
73	Genetic characterization of immortalized human prostate epithelial cell cultures. Evidence for structural rearrangements of chromosome 8 and i(8q) chromosome formation in primary tumor-derived cells. <i>Cancer Genetics and Cytogenetics</i> , 2000 , 120, 50-7		25
72	Recent advances in chemotherapy for advanced prostate cancer. <i>Current Urology Reports</i> , 2000 , 1, 48-56	2.9	4
71	Modified differential display technique that eliminates radioactivity and decreases screening time. <i>BioTechniques</i> , 2000 , 28, 272-4, 276-7	2.5	4
70	Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1941-2	9.7	27
69	Etoposide in prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2000 , 1, 271-5	4	8
68	Galectin-3 induces endothelial cell morphogenesis and angiogenesis. <i>American Journal of Pathology</i> , 2000 , 156, 899-909	5.8	354

67 Hormonal Manipulation of Prostate Cancer **2000**, 293-311

66 New Paradigms in the Management of Hormone Refractory Disease **2000**, 289-303

65 Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. *Journal of Clinical Oncology*, **1999**, 17, 1664-71 2.2 137

64 A new concept in cancer care: the supportive care program. *American Journal of Hospice and Palliative Medicine*, **1999**, 16, 713-22 2.6 18

63 Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. *Prostate*, **1999**, 39, 187-97 4.2 44

62 Oral chemotherapy in the treatment of hormone-refractory prostate cancer. *Drugs*, **1999**, 58 Suppl 3, 127-31 12.1 4

61 Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. *Urology*, **1999**, 53, 260-6 1.6 175

60 A unifying model to explain the increased incidence and higher mortality of prostate cancer in black men. *Urology*, **1999**, 53, 1073-6 1.6 10

59 Use of PC-SPEs, a commercially available supplement for prostate cancer, in a patient with hormone-naïve disease. *Urology*, **1999**, 54, 319-23; discussion 323-4 1.6 38

58 Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. *Urology*, **1999**, 54, 746-52 1.6 11

57 Early castration reduces prostatic carcinogenesis in transgenic mice. *Urology*, **1999**, 54, 1112-9 1.6 55

56 Rational use of chemotherapy. It is not just rat poison. *Urologic Clinics of North America*, **1999**, 26, 275-9, vii 2.9

55 Current Chemotherapy Regimens. *Urologic Clinics of North America*, **1999**, 26, 419-421 2.9

54 Oral chemotherapy for hormone refractory prostate cancer. The University of Michigan experience. *Urologic Clinics of North America*, **1999**, 26, 333-40 2.9 5

53 Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein **1999**, 39, 187 0

52 Hormone resistance in prostate cancer. *Cancer and Metastasis Reviews*, **1998**, 17, 373-81 9.6 57

51 LONGITUDINAL COHORT ANALYSIS OF LETHAL PROSTATE CANCER PROGRESSION IN TRANSGENIC MICE. *Journal of Urology*, **1998**, 160, 1500-1505 2.5 46

50 A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. *Urology*, **1998**, 52, 257-60 1.6 137

49	Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 118-23	9.7	183
48	Explaining Aberrations of Cell Structure and Cell Signaling in Cancer Using Complex Adaptive Systems. <i>Advances in Molecular and Cell Biology</i> , 1997 , 24, 207-247		3
47	A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. <i>Urology</i> , 1997 , 50, 401-6; discussion 406-7	1.6	75
46	Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. <i>Urology</i> , 1997 , 50, 920-8	1.6	499
45	The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. <i>Urologic Clinics of North America</i> , 1997 , 24, 433-7	2.9	7
44	Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 36-9	2.7	58
43	Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. <i>Urology</i> , 1996 , 48, 164-70	1.6	35
42	Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. <i>Urology</i> , 1996 , 48, 508-116		6
41	Epidemiology of prostate cancer: molecular and environmental clues. <i>Urology</i> , 1996 , 48, 676-83	1.6	36
40	Hormonal and Chemotherapeutic Systemic Therapy for Metastatic Prostate Cancer. <i>Cancer Control</i> , 1996 , 3, 493-500	2.2	2
39	Effect of organ site on nuclear matrix protein composition 1996 , 62, 132-141		7
38	A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996 , 19, 500-3	2.7	7
37	Role of the nuclear matrix in breast cancer. <i>Cancer Treatment and Research</i> , 1996 , 83, 127-40	3.5	1
36	Electroretinographic findings in subjects after administration of fenretinide. <i>Documenta Ophthalmologica</i> , 1995 , 91, 299-309	2.2	1
35	Inhibition of prostate cancer growth by vinblastine and tamoxifen. <i>Prostate</i> , 1995 , 26, 270-4	4.2	11
34	Inhibition of prostate cancer growth by estramustine and colchicine. <i>Prostate</i> , 1995 , 26, 310-5	4.2	24
33	Galectin-3 is a nuclear matrix protein which binds RNA. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 217, 292-303	3.4	63
32	Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. <i>Urology</i> , 1995 , 45, 93-101; discussion 101-2	1.6	95

31	Inhibition of prostate cancer growth by estramustine and etoposide. <i>Cancer</i> , 1995 , 75, 1920-1926	6.4	7
30	Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. <i>International Journal of Cancer</i> , 1995 , 63, 100-5	7.5	29
29	Oral etoposide in the treatment of hormone-refractory prostate cancer. <i>Cancer</i> , 1994 , 74, 100-3	6.4	41
28	Coupling of cell structure to cell metabolism and function. <i>Journal of Cellular Biochemistry</i> , 1994 , 55, 16-21	4.7	15
27	Alterations in cellular gene expression without changes in nuclear matrix protein content. <i>Journal of Cellular Biochemistry</i> , 1994 , 56, 502-9	4.7	1
26	Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. <i>Urology</i> , 1994 , 43, 892-9	1.6	85
25	An unstable nuclear matrix may contribute to genetic instability. <i>Medical Hypotheses</i> , 1994 , 42, 45-52	3.8	19
24	A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. <i>Cancer Letters</i> , 1993 , 70, 159-66	9.9	29
23	Risk factors for prostate cancer. <i>Annals of Internal Medicine</i> , 1993 , 118, 793-803	8	272
22	The Tissue Matrix and The Regulation of Gene Expression in Cancer Cells. <i>Advances in Molecular and Cell Biology</i> , 1993 , 7, 131-156		6
21	Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. <i>Journal of Urology</i> , 1993 , 149, 1622-5	2.5	85
20	Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. <i>Prostate</i> , 1993 , 22, 225-33	4.2	40
19	A common set of nuclear matrix proteins in prostate cancer cells. <i>Prostate</i> , 1993 , 23, 61-7	4.2	17
18	Characterization of nuclear morphology and nuclear matrices in ageing human fibroblasts. <i>Mechanisms of Ageing and Development</i> , 1992 , 62, 13-24	5.6	17
17	Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells. <i>Prostate</i> , 1992 , 20, 29-41	4.2	20
16	Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. <i>Prostate</i> , 1992 , 20, 233-41	4.2	21
15	The effect of age on the response of the detrusor to intracellular mechanical stimulus: DNA replication and the cell actin matrix. <i>Journal of Cellular Biochemistry</i> , 1992 , 48, 373-84	4.7	13
14	Nuclear-cytoskeletal interactions: evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. <i>Journal of Cellular Biochemistry</i> , 1992 , 49, 357-65	4.7	81

13	Nuclear structure and the three-dimensional organization of DNA. <i>Journal of Cellular Biochemistry</i> , 1991 , 47, 289-99	4.7	138
12	Correlation of nuclear morphometry with progression of breast cancer. <i>Cancer</i> , 1991 , 68, 2012-6	6.4	98
11	The effect of extracellular matrix interactions on morphologic transformation in vitro. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 179, 333-9	3.4	24
10	Modifications of the intermediate filament and nuclear matrix networks by the extracellular matrix. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 179, 340-4	3.4	22
9	Cellular harmonic information transfer through a tissue tensegrity-matrix system. <i>Medical Hypotheses</i> , 1991 , 34, 88-95	3.8	57
8	The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. <i>Journal of Urology</i> , 1991 , 145, 199-202	2.5	63
7	The tissue matrix: cell dynamics and hormone action. <i>Endocrine Reviews</i> , 1990 , 11, 399-417	27.2	122
6	Characterization of the subtypes of cell motility in ageing human skin fibroblasts. <i>Mechanisms of Ageing and Development</i> , 1990 , 56, 99-105	5.6	41
5	A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. <i>Journal of Cell Science</i> , 1984 , 1, 123-35	5.3	147
4	Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics456-464		
3	Cancer as a Disease: Types of Tumors, Their Frequencies, and Their Progression21-34		
2	Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy		1
1	3D Cell Nuclear Morphology: Microscopy Imaging Dataset and Voxel-Based Morphometry Classification Results		4